

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF Art Unit: 1614
Feldman, David Louis, et al. Examiner: Finn, Meghan R
INTERNATIONAL APPLICATION NO: PCT/EP2005/002809
FILED: March 16, 2005
U.S. APPLICATION NO: 10/592973
35 USC §371 DATE: November 07, 2006
FOR: USE OF RENIN INHIBITORS IN THERAPY

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In response to the Restriction Requirement dated October 6, 2008, for which the time to respond is February 6, 2009, with a time extension of three months, Applicants choose Group I, drawn to a method of treatment with the compound of Formula I. Applicants elect the absence of an additional compound. Applicants additionally elect diabetes type 2. Claims 1, 3, 7, and 8 read on the elected invention.

These elections are made for the purposes of the restriction requirement. Upon the allowance of a generic claim, Applicants reserve the option to request examination of claims to additional species which include the limitations of the allowed generic claim.

An extension of time for three months to respond to the Office Action is respectfully requested. A Petition for Extension of Time and the required fee are being filed concurrently with this Response. Applicants authorize the Commissioner to charge any fees or credit any overpayment related to the filing to this Response to Account No. 19-0134, in the name of Novartis.

Applicants have addressed all of the issues raised in the Restriction Requirement dated October 6, 2008, and respectfully request a Notice of Allowance at the Office's earliest convenience.

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
(862) 778-9499

Respectfully submitted,

A handwritten signature in dark ink, appearing to read "Joseph Majka", is written over a horizontal line.

Joseph Majka
Attorney for Applicant
Reg. No. 30,570

Date: February 5, 2009